In this Hematology Dialogues, Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies, participants will learn about the epidemiology and burden of Epstein-Barr Virus-positive (EBV+) and post-transplant lymphoproliferative disorders (PTLD), differentiate between current and emerging prognostic scoring systems for EBV+ and PTLD to inform treatment decisions, and evaluate the latest clinical evidence of emerging treatment options for EBV+ and PTLD. Experts will discuss hot topics in the field of EBV+ and PTLD as well as respond to patient cases and provide commentary relating to how they have responded to complex treatment decisions, thereby ensuring optimal clinical outcomes.
This independent satellite symposium is derived from the Society of Hematologic Oncology 2024 Annual Meeting, originally held on September 5, 2024.
Speakers
Kris M. Mahadeo, MD, MPH
Division Chief
Pediatric Transplant & Cellular Therapy
Duke Cancer Institute
Duke University School of Medicine
Durham, NC, USA
Dr. Kris Michael Mahadeo, MD, MPH is the Division Chief of Pediatric Transplant and Cellular Therapy (PCTC) at Duke University. The Division of Pediatric Transplant and Cellular Therapy (PTCT) in the Duke Department of Pediatrics is an internationally-renowned transplant program with an established history of innovation in the care of children, adolescent and young adults with rare diseases. Duke PTCT has performed more than 2,500 transplants in children and young adults with over 100 unique diagnoses for patients from all over the world. Dr. Mahadeo’s clinical research is focused on mitigating toxicity and management of critical care complications associated with cellular therapies. He is a global leader in international harmonization for the diagnosis and severity grading of unique complications of Immune Effector cell Therapies and has also led international efforts across several academic societies to provide updated diagnostic criteria for sinusoidal obstructive syndrome. Dr. Mahadeo was the first author on the recently published manuscript in Lancet Oncology with the ALLELE trial, a phase 3 multi-center study of EBV CTLs for refractory/relapsed PTLD.
Timothy Voorhees, MD, MSCR
Assistant Professor of Internal Medicine –
Clinical Division of Hematology
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center
Columbus, OH, USA
A hematologist/oncologist with a clinical focus in lymphoid malignancies, specifically B-cell lymphomas. His research focus involves the design and implementation of early phase clinical trials for patients with lymphoma. He is most interested in advancing novel immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies, bi-specific antibody therapies and other antibody-based therapies in a variety of B-cell lymphoma subtypes. He has a specific interest in post transplantation lymphoproliferative disorders (PTLD) as well as Epstein-Barr virus (EBV) lymphomagenesis. He has a designed and implemented multiple early phase clinical trials for patients with PTLD.
Sarah Featherston, RN, CPN, BMTCN
Pediatric Stem Cell Transplant Coordinator
Children’s Cancer Hospital
MD Anderson Cancer Center
Houston, TX, USA
Coming soon
Accreditation and Disclosure Information
Target Audience
This activity is intended for hematologists, hematology-oncologists, pediatric hematologists, pediatricians, internists, and nurse practitioners (NPs), PAs, and nurses who provide care to individuals with EBV+ PTLD.
Educational Objectives
After completing this activity, the participant should be better able to:
- Summarize the epidemiology and burden of EBV+ PTLD
- Differentiate among current and emerging prognostic scoring systems for EBV+ PTLD in order to inform treatment decisions
- Evaluate the latest clinical evidence of emerging treatment options for EBV+ PTLD, based on safety, efficacy, mechanism of action, treatment- and disease-specific factors to determine optimal treatment strategies for patients with EBV+ PTLD
Agenda
Understanding EBV+ PTLD
- Epidemiology
- Burden
- Diagnosis
- Experts React: Causes of the Increasing Incidence of EBV+ PTLD
Prognostic Challenges
- Disease Specific Features
- Patient Specific Features
- Risk Factors for Poor Prognosis in SOT recipients
- Risk Factors for Poor Prognosis in allo-HCT recipients
- Current scoring systems and their limitations
- Experts React: Estimating Survival Risk for Patients
Game-Changing Emerging Agents for EBV+ PTLD
- Overall Treatment Concerns
- Chemotherapy
- Emerging EBV+ Targeted Therapies: Key Clinical data
- Guidelines
- Experts React: The Promise of New Options for EBV+ PTLD
Q&A with Expert Faculty
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
PA
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until September 24, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
ILNA Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
1.0 points: Care Continuum (OCN, CBCN, CPHON, AOCNP); Disease Related Biology (CPHON); Early Post- Transplant Management and Education (BMTCN); Foundations of Transplant (BMTCN); Late Post-Transplant Management and Education (BMTCN)
1.0 points: Oncologic Emergencies (OCN, CPHON, AOCNP); Oncology Nursing Practice (OCN); Pediatric Hematology and Oncology Nursing Practice (CPHON); Professional Practice/Performance (BMTCN, AOCNP); Quality of Life (BMTCN); Roles of the APRN (AOCNP); Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP); Transplant Process and Infusion (BMTCN); Treatment (OCN, CBCN, AOCNP, CPHON)
The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.
EBAH Credit
Medical Learning Institute, Inc. is an accredited CME-CPD provider by the European Board for Accreditation in Hematology (EBAH).
This educational activity has been accredited for a maximum number of 1.0 EBAH CME-CPD credits. Each participant should only collect credits for time that she/he actually spent in the educational activity.
How to collect your EBAH CME credits:
You can also use the direct link to the account creation / login page:
- Creating a CME account or logging in is simple and free of cost.
- Please inform your details to event organizer, so they can add your EBAH-CME credit points.
Within the EBAH-CME system, you can:
- Print your EBAH-CME certificates.
- Review and manage your personal account.
- Search for accredited events based on the European Hematology Curriculum.
For further assistance please contact:
EBAH Office Koninginnegracht 12b, 2514 AA – The Hague, The Netherlands Phone: +31 (0)70 3020 099
Email: info@ebah.org
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
This activity is supported by an educational grant from Pierre Fabre. In-Kind support provided by National Marrow Donor Program (NMDP) and American Society for Transplantation and Cellular Therapy (ASTCT).
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Kris M. Mahadeo, MD, MPH
Division Chief
Pediatric Transplant & Cellular Therapy
Duke Cancer Institute
Duke University School of Medicine
Durham, NC, USA
Kris M. Mahadeo, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Research Funding: Adaptimmune, Jazz, Syndax
The following relationships have ended within the last 24 months:
Consultant/Advisor (ended 2023): Atara, Jazz, Vertex
Planner/Presenter
Timothy Voorhees, MD, MSCR
Assistant Professor of Internal Medicine – Clinical
Division of Hematology
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center
Columbus, OH, USA
Timothy Voorhees, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Speaker’s Bureau: AbbVie, Genmab, Incyte, Kite, MorphoSys, Recordati, Viracta
The following relationships have ended within the last 24 months:
Consultant/Advisor: Genmab (ended March 2024); Novartis (ended August 2023), Recordati (ended Dec 2023)
Guest Speaker
Sarah Featherston, RN, CPN, BMTCN
Pediatric Stem Cell Transplant Coordinator
Children’s Cancer Hospital
MD Anderson Cancer Center
Houston, TX, USA
Sarah Featherston, RN, CPN, BMTCN, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Speaker’s Bureau (ended July 2024): Jazz Pharmaceuticals
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical learning Institute, Inc.
If you have questions regarding the receipt of your certificate, please contact via email at mvu@mlieducation.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
For Physicians requesting EBAH credit, please provide your EBAH personal account number.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute, Inc. All Rights Reserved.